Cloniprazepam is a benzodiazepine derivative and a prodrug mainly for clonazepam (a patented medicine) and other metabolites.,[1][2] including 7-aminoclonazepam and clonazepam mentioned above (both as metabolites), which may be misinterpreted as clonazepam intake at the result of a drug test.[1]
Some of the minor metabolites include 3-hydroxy and 6-hydroxyclonazepam, 3-hydroxycloniprazepam and ketocloniprazepam with ketone group formed where 3-hydroxy group was.[1]
It is a designer drug and an NPS (short for "new psychoactive substance").[1] At the end of 2017, cloniprazepam remains an uncontrolled substance in most of the countries.
^ abcdMoosmann B, Bisel P, Franz F, Huppertz LM, Auwärter V (November 2016). "Characterization and in vitro phase I microsomal metabolism of designer benzodiazepines - an update comprising adinazolam, cloniprazepam, fonazepam, 3-hydroxyphenazepam, metizolam and nitrazolam". Journal of Mass Spectrometry. 51 (11): 1080–1089. Bibcode:2016JMSp...51.1080M. doi:10.1002/jms.3840. PMID27535017.
^Mortelé O, Vervliet P, Gys C, Degreef M, Cuykx M, Maudens K, et al. (May 2018). "In vitro Phase I and Phase II metabolism of the new designer benzodiazepine cloniprazepam using liquid chromatography coupled to quadrupole time-of-flight mass spectrometry". Journal of Pharmaceutical and Biomedical Analysis. 153: 158–167. doi:10.1016/j.jpba.2018.02.032. hdl:10067/1496330151162165141. PMID29494888. S2CID3946404.
